Germany Merck Present Tender

Merck a leading science and technology company today announced research from Company-sponsored investigator-sponsored and collaborative studies including two oral and two mini-oral presentations at this years World Conference on Lung Cancer September 8-14 2021 and the European Society for Medical Oncology ESMO Congress September 16-21 2021.Analyses presented from ongoing and completed trials at both of these meetings have the potential to make a difference for patients by meaningfully informing treatment decisions in challenging tumors such as lung and bladder cancers said Danny Bar-Zohar Global Head of Development for the Healthcare business of Merck.Select presentations includeBAVENCIO avelumabReal-world evidence will be presented supporting the continued need for first-line treatments for advanced urothelial carcinoma. Data from an investigator-sponsored study of avelumab in combination with neoadjuvant chemotherapy to treat muscle-invasive bladder cancer will be presented for the first time. BAVENCIO has been approved in multiple countries as a first-line maintenance treatment of metastatic UC that has not progressed with first-line platinum containing chemotherapy based on a statistically significant overall survival benefit in a Phase III clinical study.TepotinibData for oral MET inhibitor tepotinib at IASLC 2021 World Conference on Lung Cancer WCLC 2021 and ESMO includeData from the VISION trial the largest study of patients with METex14 skipping NSCLC prospectively enrolled based on liquid andor tissue biopsy n275New results demonstrating robust and durable efficacy and manageable safetyFirst-time results in key age subgroups including patients 75 years.A trial-in-progress update from the ongoing INSIGHT 2 study in EGFR-mutant NSCLC with MET amplification.Berzosertib M6620For the leading asset in the Companys DDR inhibitor program a first-time look at the ongoing Phase II study of ATR inhibitor berzosertib in patients with relapsed platinum-resistant small cell lung cancer SCLC will be presented.ERBITUX cetuximabERBITUX continues to demonstrate in a number of studies its significant role as the backbone of treatment in metastatic colorectal cancer.Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways immuno-oncology and DNA Damage Response DDR to tackle challenging tumor types in gastrointestinal genitourinary and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers as we work to illuminate a path to scientific breakthroughs that transform patient outcomes.